# Safety of Vascugel Treatment After Creation of Arteriovenous Access for Hemodialysis Use

> **NCT00479180** · PHASE1,PHASE2 · COMPLETED · sponsor: **Pervasis Therapeutics, Inc** · enrollment: 65 (actual)

## Conditions studied

- Hemodialysis Access

## Interventions

- **BIOLOGICAL:** Vascugel
- **BIOLOGICAL:** Placebo Comparator

## Key facts

- **NCT ID:** NCT00479180
- **Lead sponsor:** Pervasis Therapeutics, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-07
- **Primary completion:** 2010-06
- **Final completion:** 2010-06
- **Target enrollment:** 65 (ACTUAL)
- **Last updated:** 2011-10-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00479180

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00479180, "Safety of Vascugel Treatment After Creation of Arteriovenous Access for Hemodialysis Use". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00479180. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*